BRPI0502497A - uso de agonistas e antagonistas do receptor acoplado a proteìna g, mas, como moduladores de atividade apoptótica para o estudo, a prevenção e o tratamento de doenças - Google Patents
uso de agonistas e antagonistas do receptor acoplado a proteìna g, mas, como moduladores de atividade apoptótica para o estudo, a prevenção e o tratamento de doençasInfo
- Publication number
- BRPI0502497A BRPI0502497A BRPI0502497-8A BRPI0502497A BRPI0502497A BR PI0502497 A BRPI0502497 A BR PI0502497A BR PI0502497 A BRPI0502497 A BR PI0502497A BR PI0502497 A BRPI0502497 A BR PI0502497A
- Authority
- BR
- Brazil
- Prior art keywords
- antagonists
- protein
- apoptotic activity
- coupled receptor
- receptor agonists
- Prior art date
Links
- 230000001640 apoptogenic effect Effects 0.000 title abstract 7
- 238000011282 treatment Methods 0.000 title abstract 6
- 229940044601 receptor agonist Drugs 0.000 title abstract 5
- 239000000018 receptor agonist Substances 0.000 title abstract 5
- 229940044551 receptor antagonist Drugs 0.000 title abstract 5
- 239000002464 receptor antagonist Substances 0.000 title abstract 5
- 230000002265 prevention Effects 0.000 title abstract 4
- 201000010099 disease Diseases 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 6
- 101710120037 Toxin CcdB Proteins 0.000 abstract 3
- 210000000056 organ Anatomy 0.000 abstract 3
- 108091008611 Protein Kinase B Proteins 0.000 abstract 2
- 239000000556 agonist Substances 0.000 abstract 2
- 239000005557 antagonist Substances 0.000 abstract 2
- 229940080349 GPR agonist Drugs 0.000 abstract 1
- 229940123344 GPR antagonist Drugs 0.000 abstract 1
- PVHLMTREZMEJCG-GDTLVBQBSA-N Ile(5)-angiotensin II (1-7) Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 PVHLMTREZMEJCG-GDTLVBQBSA-N 0.000 abstract 1
- 102000005765 Proto-Oncogene Proteins c-akt Human genes 0.000 abstract 1
- 230000004075 alteration Effects 0.000 abstract 1
- 239000000969 carrier Substances 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 210000001671 embryonic stem cell Anatomy 0.000 abstract 1
- 238000002513 implantation Methods 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/085—Angiotensins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
"USO DE AGONISTAS E ANTAGONISTAS DO RECEPTOR ACOPLADO à PROTEìNA G, MAS, COMO MODULADORES DE ATIVIDADE APOPTóTICA PARA O ESTUDO, PREVENçãO E TRATAMENTO DE DOENçAS". A presente invenção está caracterizada pelo uso de agonistas e antagonistas do receptor acoplado à proteína G, MAS, como moduladores de atividade apoptótica para uso no estudo, prevenção e tratamento de doenças. Caracteriza-se ainda pelo uso de agonistas e antagonistas do receptor acoplado à proteína G, Mas, para modulação da atividade apoptótica envolvendo alterações da atividade da proteína quinase B/Akt. Uma outra característica da invenção é o uso de agonistas e antagonistas do receptor acoplado à proteína G, Mas, incluindo o peptídeo Ang-(1-7) e seus análogos, agonistas e antagonistas, peptídicos ou não peptídicos como moduladores da atividade apoptótica para uso no estudo, prevenção e tratamento de doenças degenerativos de órgãos e sistemas, como medida auxiliar para transplantes de órgãos, tratamento com células tronco embrionárias, não embrionárias, re-implante de órgãos e tecidos e outros tratamentos que necessitem redução temporária ou crónica da atividade apoptótica, não limitantes. A invenção reivindica ainda uso de agonistas e antagonistas do receptor acoplado à proteína G, MAS, incluindo o peptídeo Angiotensina-(17) e seus análogos, agonistas e antagonistas, peptídicos ou não peptídicos formulados com excipientes ou carreadores aceitáveis farmacêutica e farmacologicamente, como moduladores da atividade apoptótica.
Priority Applications (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BRPI0502497-8A BRPI0502497A (pt) | 2005-06-28 | 2005-06-28 | uso de agonistas e antagonistas do receptor acoplado a proteìna g, mas, como moduladores de atividade apoptótica para o estudo, a prevenção e o tratamento de doenças |
| EP06741348A EP1904087A2 (en) | 2005-06-28 | 2006-06-28 | Use of mas g-protein-coupled receptor agonists and antagonists as apoptotic activity modulators for prevention and treatment of diseases |
| JP2008518575A JP2008546811A (ja) | 2005-06-28 | 2006-06-28 | 病気の研究、予防及び治療のためのアポトーシス活性調節剤としての、ｍａｓｇ−タンパク質結合受容体アゴニスト及びアンタゴニストの使用 |
| PCT/BR2006/000125 WO2007000036A2 (en) | 2005-06-28 | 2006-06-28 | Use of mas g-protein-coupled receptor agonists and antagonists as apoptotic activity modulators for prevention and treatment of diseases |
| US11/922,949 US20080312129A1 (en) | 2005-06-28 | 2006-06-28 | Use of Mas G-Protein-Coupled Receptor Agonists and Antagonists, as Apoptotic-Activity Modulators for Study, Prevention and Treatment of Diseases |
| CA002613126A CA2613126A1 (en) | 2005-06-28 | 2006-06-28 | Use of mas g-protein-coupled receptor agonists and antagonists as apoptotic activity modulators for prevention and treatment of diseases |
| CNA2006800302306A CN101247818A (zh) | 2005-06-28 | 2006-06-28 | Mas g-蛋白偶联受体激动剂和拮抗剂作为凋亡活性调节剂用于预防和治疗疾病的用途 |
| JP2013000248A JP2013075911A (ja) | 2005-06-28 | 2013-01-04 | 病気の研究、予防及び治療のためのアポトーシス活性調節剤としての、ｍａｓｇ−タンパク質結合受容体アゴニスト及びアンタゴニストの使用 |
| JP2017036611A JP2017114901A (ja) | 2005-06-28 | 2017-02-28 | 病気の研究、予防及び治療のためのアポトーシス活性調節剤としての、ｍａｓ ｇ−タンパク質結合受容体アゴニスト及びアンタゴニストの使用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BRPI0502497-8A BRPI0502497A (pt) | 2005-06-28 | 2005-06-28 | uso de agonistas e antagonistas do receptor acoplado a proteìna g, mas, como moduladores de atividade apoptótica para o estudo, a prevenção e o tratamento de doenças |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0502497A true BRPI0502497A (pt) | 2007-02-06 |
Family
ID=37595483
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0502497-8A BRPI0502497A (pt) | 2005-06-28 | 2005-06-28 | uso de agonistas e antagonistas do receptor acoplado a proteìna g, mas, como moduladores de atividade apoptótica para o estudo, a prevenção e o tratamento de doenças |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20080312129A1 (pt) |
| EP (1) | EP1904087A2 (pt) |
| JP (3) | JP2008546811A (pt) |
| CN (1) | CN101247818A (pt) |
| BR (1) | BRPI0502497A (pt) |
| CA (1) | CA2613126A1 (pt) |
| WO (1) | WO2007000036A2 (pt) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113207799A (zh) * | 2021-03-19 | 2021-08-06 | 中山大学 | 一种二型糖尿病小鼠快速心衰模型的构建方法 |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0602366B1 (pt) | 2006-04-26 | 2017-12-12 | Universidade Federal De Minas Gerais | Use of agonists of the receptor coupled to protein g, but, in the treatment of metabolic syndrome, its components and their complications |
| WO2008052295A1 (en) * | 2006-10-30 | 2008-05-08 | Universidade Federal De Minas Gerais | Process for the preparation of compounds of at1 receptor antagonists with angiotensin-(1-7), analogues thereof and/or mixtures of these systems, pharmaceutical compositions thereof and use of their derivative products |
| BRPI0806230A2 (pt) * | 2007-01-26 | 2021-05-25 | Universidade Federal De Minas Gerais - Ufmg | composições farmacêuticas, método para tratar a disfunção erétil e método para restaurar a capacidade de ereção |
| BRPI0800585B8 (pt) | 2008-02-13 | 2021-05-25 | Univ Minas Gerais | composições farmacêuticas do peptídeo des-[asp1]-[ala1]-angiotensina-(1-7) e uso do peptídeo des-[asp1]-[ala1]-angiotensina-(1-7) |
| ES2393455T3 (es) | 2008-09-12 | 2012-12-21 | Charité-Universitátsmedizin Berlin (Charité) | Uso de un agonista del receptor Ang-(1-7) en lesiones pulmonares agudas |
| DE102009013456A1 (de) * | 2009-03-18 | 2010-09-23 | GÖPFERICH, Achim, Prof. Dr. | Nanopartikel für die Erkennung von Zellen, durch Bindung an G-Protein gekoppelte Rezeptoren |
| CN102337298B (zh) * | 2011-08-19 | 2013-11-06 | 黄开红 | 一种输送siRNA的免疫纳米载体及其制备方法和应用 |
| US20130210726A1 (en) * | 2012-02-10 | 2013-08-15 | Tarix Pharmaceuticals Ltd. | Compositions and methods for treatment of peripheral vascular disease |
| US8557958B1 (en) | 2012-06-18 | 2013-10-15 | Tarix Pharmaceuticals Ltd. | Compositions and methods for treatment of diabetes |
| US8633158B1 (en) * | 2012-10-02 | 2014-01-21 | Tarix Pharmaceuticals Ltd. | Angiotensin in treating brain conditions |
| BR132012028005E2 (pt) * | 2012-10-31 | 2014-11-18 | Univ Minas Gerais | Composições farmacêuticas contendo um agonista do receptor mas para o tratamento de doenças degenerativas musculares. |
| AU2014284496A1 (en) * | 2013-07-03 | 2016-01-21 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Method for treating cognitive dysfunction |
| US9333233B2 (en) | 2014-02-25 | 2016-05-10 | Tarix Pharmaceuticals Ltd. | Methods and compositions for the delayed treatment of stroke |
| US10183055B2 (en) | 2014-07-21 | 2019-01-22 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Ang-(1-7) derivative oligopeptides for the treatment of pain and other indications |
| CN106535920B (zh) | 2014-07-21 | 2020-10-30 | 代表亚利桑那大学的亚利桑那校董会 | Ang-(1-7)衍生物寡肽及其使用和生产方法 |
| EP4371556B1 (en) | 2022-11-15 | 2026-08-05 | Explicat Pharma GmbH | Angiotensin(1-7) pharmaceutical compositions for inhalation |
| CN116355856A (zh) * | 2023-04-19 | 2023-06-30 | 陕西慧康生物科技有限责任公司 | 一种人mas1过表达细胞株及其构建方法和应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6989363B1 (en) * | 1997-12-11 | 2006-01-24 | Millennium Pharmaceuticals, Inc. | Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therefor |
| WO1999065531A1 (en) * | 1998-06-18 | 1999-12-23 | Johns Hopkins University School Of Medicine | Polymers for delivery of nucleic acids |
| US6236766B1 (en) * | 1998-09-11 | 2001-05-22 | General Electric Company | Method and apparatus for zooming digital images |
| AU772731B2 (en) * | 1998-10-02 | 2004-05-06 | Caritas St. Elizabeth's Medical Center Of Boston, Inc. | AKT compositions for enhancing survival of cells |
| JP2002527489A (ja) * | 1998-10-22 | 2002-08-27 | キュラゲン コーポレイション | 腎疾患および関連疾患に対する予想および治療的遺伝子およびタンパク質 |
| JP2003524624A (ja) * | 1999-04-09 | 2003-08-19 | ジェシー エル エス オウ | 治療薬の組織への送達を高める方法及び組成物 |
| YU78601A (sh) * | 1999-05-05 | 2005-07-19 | Aventis Pharma Deutschland Gmbh. | 1-(p-tienilbenzil)-imidazoli kao agonisti angiotenzin-(1-7)- receptora, postupak za njihovu proizvodnju, njihova primena i farmaceutski preparati koji ih sadrže |
| WO2000071584A1 (en) * | 1999-05-20 | 2000-11-30 | Human Genome Sciences, Inc. | Seven transmembrane receptor genes |
| EP1268783B9 (en) * | 2000-03-29 | 2007-01-17 | Beth Israel Deaconess Medical Center, Inc. | Antiangiogene Eigenschaften von Matin und Fragmenten oder Varianten davon |
| JP2003532623A (ja) * | 2000-06-30 | 2003-11-05 | バイエル アクチェンゲゼルシャフト | 抗脈管形成性アンジオテンシン−７およびそれをコードするポリヌクレオチドを使用することによる脈管形成の調節方法 |
| CA2430719A1 (en) * | 2000-12-22 | 2002-07-04 | Astrazeneca Ab | A method of assaying for agonists or antagonist of dynorphin a binding to the mas receptor |
| BRPI0105509B8 (pt) * | 2001-11-05 | 2021-05-25 | Univ Minas Gerais | formulações do peptídeo angiotensina-(1-7) usando as ciclodextrinas, lipossomas e o polímero plga |
| AU2003217783A1 (en) * | 2002-02-27 | 2003-09-09 | Wake Forest University | Angiotensin-(1-7) and angiotensin-(1-7) agonists for inhibition of cancer cell growth |
| WO2006005470A2 (en) * | 2004-07-15 | 2006-01-19 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with mas related g-protein coupled receptor e (mrge) |
| BRPI0503122A (pt) * | 2005-05-30 | 2007-05-02 | Univ Minas Gerais | composições farmacêuticas do peptìdeo angiotensina-(1-7) [ang-(1-7)] e seus análogos, agonistas e antagonistas usando as ciclodextrinas, seus derivados, e o polìmeros biodegradáveis e/ou dos produtos derivados para uso no controle das funções do sistema reprodutivo |
-
2005
- 2005-06-28 BR BRPI0502497-8A patent/BRPI0502497A/pt not_active Application Discontinuation
-
2006
- 2006-06-28 US US11/922,949 patent/US20080312129A1/en not_active Abandoned
- 2006-06-28 WO PCT/BR2006/000125 patent/WO2007000036A2/en not_active Ceased
- 2006-06-28 EP EP06741348A patent/EP1904087A2/en not_active Withdrawn
- 2006-06-28 CN CNA2006800302306A patent/CN101247818A/zh active Pending
- 2006-06-28 JP JP2008518575A patent/JP2008546811A/ja not_active Withdrawn
- 2006-06-28 CA CA002613126A patent/CA2613126A1/en not_active Abandoned
-
2013
- 2013-01-04 JP JP2013000248A patent/JP2013075911A/ja active Pending
-
2017
- 2017-02-28 JP JP2017036611A patent/JP2017114901A/ja active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113207799A (zh) * | 2021-03-19 | 2021-08-06 | 中山大学 | 一种二型糖尿病小鼠快速心衰模型的构建方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101247818A (zh) | 2008-08-20 |
| CA2613126A1 (en) | 2007-01-04 |
| EP1904087A2 (en) | 2008-04-02 |
| WO2007000036A2 (en) | 2007-01-04 |
| JP2013075911A (ja) | 2013-04-25 |
| US20080312129A1 (en) | 2008-12-18 |
| JP2017114901A (ja) | 2017-06-29 |
| WO2007000036A3 (en) | 2007-05-18 |
| JP2008546811A (ja) | 2008-12-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2007000036A3 (en) | Use of mas g-protein-coupled receptor agonists and antagonists as apoptotic activity modulators for prevention and treatment of diseases | |
| DOP2010000097A (es) | Anticuerpos especificos para la forma de protofibrillas de la proteina beta-amiloide | |
| ECSP034810A (es) | Derivados heterociclilalcoxi-, -alquiltio- y - alquilaminobenzazol tales como ligandos 5-hidroxitriptamina-6 | |
| BR0314052A (pt) | Imidazolpiridinas e métodos para sua fabricação e uso | |
| BR0210886A (pt) | Composto, composição farmacêutica, uso de um composto, e, métodos de geração de imagens, de monitoração do efeito do tratamento de um corpo humano ou animal com uma droga para combater uma condição associada com câncer e de tratamento de câncer ou de uma doença relacionada em um corpo humano ou animal | |
| Martin et al. | Involvement of autophagy in melatonin‐induced cytotoxicity in glioma‐initiating cells | |
| BRPI0414062B8 (pt) | uso de ciclosporinas modificadas para o tratamento de distúrbios por hcv | |
| BR0208636A (pt) | Agente terapêutico para doenças de artrìtides crÈnicas de doenças relacionadas com infncia | |
| GT200800214A (es) | Antagonistas de los piridil amida de los canales de calcios de tipo t | |
| ECSP088350A (es) | Pirazolopirimidinas como inhibidores de protein quinasas | |
| CL2009000400A1 (es) | Compuestos heterociclicos derivados de 3-fenil-1,6- naftiridin-2-ona; moduladores de la actividad cinasa; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como trastornos alergicos, trastornos autoinmunes, neoplasias, rechazo en trasplante de organos, entre otras. | |
| BRPI0509863A (pt) | liberação de fármaco para fundo de olho | |
| BRPI0409910A (pt) | métodos para o tratamento de doenças relacionadas com interleucina-6 | |
| BRPI0921999B8 (pt) | uso de uma quantidade terapeuticamente eficaz de células tronco placentárias | |
| BR112014019776A2 (pt) | composições e métodos para o tratamento de doença vascular periférica | |
| HN2005000795A (es) | Pirimidinas como antagonistas del receptor de prostaglandina d2 | |
| CR9957A (es) | Uso de un anatagonista de cb1 para tratar efectos secundarios y sintomas negativos de la esquizofrenia | |
| CL2004000827A1 (es) | Compuestos derivados de 1,2-diazoles o 1,3-diazoles condensados con un heterociclo, composicion farmaceutica; y uso para tratar enfermedades moduladas por antagonistas de receptores canabinoides, tales como obesidad y sobrepeso. | |
| GT200800265A (es) | Pirido (3,2-e)piracinas, su uso como inhibidores de fosfadiesterasa 10, y procesos para prepararlas. | |
| SV2008002511A (es) | Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos | |
| DOP2002000429A (es) | Imidazotriazinas | |
| CO6321241A2 (es) | Derivados de 1,3,4- tiadiazol espiro condensados para la inhibicion de la actividad de quinesina (ksp) | |
| ATE493412T1 (de) | Spirohydantoin-aryl-cgrp-rezeptorantagonisten | |
| ECSP045156A (es) | Derivados de indolilalquilamina como ligandos 5-hidroxitriptamina-6 | |
| BRPI0518105A (pt) | uso de antagonista da angiogênese e uso de anticorpo anti-vegf |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B11E | Dismissal acc. art. 34 of ipl - requirements for examination incomplete | ||
| B12F | Other appeals [chapter 12.6 patent gazette] | ||
| B08E | Application fees: payment of additional fee required [chapter 8.5 patent gazette] | ||
| B08G | Application fees: restoration [chapter 8.7 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08H | Application fees: decision cancelled [chapter 8.8 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 8.6 NA RPI NO 2476 DE 19/06/2018 POR TER SIDO INDEVIDA. |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 13A ANUIDADE |
|
| B08H | Application fees: decision cancelled [chapter 8.8 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 8.6 NA RPI NO 2580 DE 16/06/2020 POR TER SIDO INDEVIDA. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: NAO HOUVE MANIFESTACAO AO 7.1 (RPI 2635, 06/07/21). ASSIM, INDEFIRO O PEDIDO, CF ART.25 DA LPI (LEI 9279/96). |
|
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL |